Histone Deacetylase (HDAC) Inhibitors Market Report 2024

The histone deacetylase (HDAC) inhibitors market size has grown strongly in recent years. It will grow from $1.15 billion in 2023 to $1.23 billion in 2024 at a compound annual growth rate (CAGR) of 7.3%. The increase observed in the historical period can be attributed to several factors, including enhanced funding for epigenetic research, a growing prevalence of drug-resistant cancers, higher healthcare spending, increased use of HDAC inhibitors in veterinary medicine, and greater investment in bioinformatics.

The histone deacetylase (HDAC) inhibitors market size is expected to see strong growth in the next few years. It will grow to $1.65 billion in 2028 at a compound annual growth rate (CAGR) of 7.6%. The anticipated growth during the forecast period is driven by the rising incidence of neurodegenerative disorders, heightened awareness of cancer, increased investment in drug development, a growing number of clinical trials, and greater adoption of personalized medicine. Key trends expected during this period include advancements in technology, the expansion of personalized medicine, synergies in cancer immunotherapy, integration of digital health solutions, and developments in bioinformatics.

The increasing prevalence of neurodegenerative disorders is anticipated to drive the growth of the histone deacetylase (HDAC) inhibitors market. Neurodegenerative disorders, which involve the progressive deterioration and death of neurons in the brain and spinal cord, result in cognitive and motor impairments. Examples include Alzheimer's disease, characterized by memory loss and cognitive decline due to amyloid plaques and tau tangles. Factors contributing to the rising incidence of these disorders include aging, increased longevity, genetic predispositions, and environmental influences. HDAC inhibitors are being investigated as potential treatments for neurodegenerative conditions because they can modulate gene expression and offer neuroprotective benefits. For instance, as reported by the National Institutes of Health (NIH) in March 2021, 6.2 million older Americans were living with Alzheimer's dementia, a number expected to grow to 13.8 million by 2060. Consequently, the increasing occurrence of neurodegenerative disorders is fueling the expansion of the HDAC inhibitors market.

Key players in the HDAC inhibitors market are concentrating on developing novel treatments, such as HDAC inhibitors for cancer therapy, to improve efficacy and minimize side effects. HDAC inhibitors are a class of drugs used in cancer therapy that work by blocking HDAC enzymes, which usually remove acetyl groups from histone proteins. This blockage results in increased acetylation of histones, altering chromatin structure and affecting gene expression. For example, in September 2023, Shuttle Pharmaceuticals Holdings Inc., a US-based firm specializing in pioneering cancer therapies, received new patents from the U.S. Patent and Trademark Office for HDAC inhibitors targeting cancer treatment. These new inhibitors are designed to target specific HDAC enzymes associated with cancer progression, aiming to disrupt abnormal gene expression linked to tumor development and spread. The patented compounds offer improved potency and selectivity, reducing off-target effects and enhancing safety for patients.

In October 2021, Abcam plc, a UK-based biotechnology company, acquired BioVision Inc. for $340 million. This acquisition is intended to bolster Abcam’s life sciences portfolio, potentially expanding its range of research reagents and tools. BioVision Inc., a US-based firm, supplies research reagents and kits, including inhibitors targeting various proteins such as HDACs (Histone Deacetylases).

Major companies operating in the histone deacetylase (HDAC) inhibitors market are Bristol-Myers Squibb Company, Novartis AG, Merck KGaA, Abcam plc, Pharmacyclics LLC, R&D Systems Inc., Tenaya Therapeutics Inc., Syndax Pharmaceuticals Inc., Italfarmaco SpA, InvivoGen Corporation, TCI Chemicals (India) Pvt. Ltd., 4SC AG, Medivir AB, Mirati Therapeutics Inc., Spectrum Pharmaceuticals Inc., Curis Inc., Acetylon Pharmaceuticals Inc., Oryzon Genomics SA, Xynomic Pharmaceuticals Inc., Celleron Therapeutics Ltd., Midatech Pharma PLC, Karus Therapeutics Ltd., Shenzhen Chipscreen Biosciences Co. Ltd.

North America was the largest region in the histone deacetylase (HDAC) inhibitors market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the histone deacetylase (HDAC) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the histone deacetylase (HDAC) inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Histone deacetylase (HDAC) inhibitors are a category of compounds that inhibit the activity of histone deacetylase enzymes. These enzymes are responsible for the removal of acetyl groups from histone proteins, resulting in a more compact chromatin structure and decreased gene expression. By promoting hyperacetylation of histones, HDAC inhibitors generally lead to a more open chromatin structure, making DNA more accessible to transcription factors.

Histone deacetylase (HDAC) inhibitors are categorized into four main classes class I, class II, class III, and class IV HDACs. Class I HDACs primarily regulate gene expression by altering chromatin structure and are involved in numerous cellular processes. They are extensively researched for their potential use in treating cancer and other diseases. HDAC inhibitors can be administered orally or parenterally and are applied in fields such as oncology and neurology. They are utilized by various end users, including hospitals, academic and research institutes, and pharmaceutical companies.

The histone deacetylase (HDAC) inhibitors market research report is one of a series of new reports that provides histone deacetylase (HDAC) inhibitors market statistics, including histone deacetylase (HDAC) inhibitors industry global market size, regional shares, competitors with a histone deacetylase (HDAC) inhibitors market share, detailed histone deacetylase (HDAC) inhibitors market segments, market trends, and opportunities, and any further data you may need to thrive in the histone deacetylase (HDAC) inhibitors industry. This histone deacetylase (HDAC) inhibitors research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The histone deacetylase (HDAC) inhibitors market consists of sales of valproic acid, hydroxamic acids, cyclic peptides, short-chain fatty acids, and benzamides. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.